News & Commentary on Prescription Drug & Medical Device Lawsuits
From The Netherlands, a team of medical researchers led by E.J. Mulder published a study titled “Selective serotonin reuptake inhibitors affect neurobehavioral development in the human fetus.” in the September, 2011 edition of Neuropsychopharmacology examining the relationship between exposure to selective serotonin reuptake inhibitor drugs (SSRIs) and adverse birth outcomes.
The team…
An article titled “SSRI antidepressants: altered psychomotor development following exposure in utero?” that appeared in the February, 2013 edition of Prescrire International examines additional risks of prenatal exposure to selective serotonin reuptake inhibitor drugs (SSRIs). To be clear, a number of other studies have linked adverse birth outcomes linked to SSRI exposure…
Last summer, a team of researchers from University of British Columbia (Vancouver) led by G.E. Hanley published a study titled “Infant developmental outcomes following prenatal exposure to antidepressants, and maternal depressed mood and positive affect.” in Early Human Development. This study examined the relationship between poor early childhood development and gestational exposure…
Titled “Further findings linking SSRIs during pregnancy and persistent pulmonary hypertension of the newborn: clinical implications.”, this article appearing in the October, 2012 edition of CNS Drugs by M. Galbally et al., identifies persistent pulmonary hypertension of the newborn (PPHN) as a potential consequence of SSRI exposure before birth.
Galbally et al.
A team of researchers from Sydney, Australia (led by M.P. Austin) published an article in a December, 2006 edition of Psychological Medicine titled “To treat or not to treat: maternal depression, SSRI use in pregnancy and adverse neonatal effects.” that attempted to clarify negative consequences of prenatal exposure to SSRI drugs like Prozac…
An article in Early Human Development (February, 2013) by M.V. Smith et al. titled “Neurobehavioral assessment of infants born at term and in utero exposure to serotonin reuptake inhibitors.”, from The Yale School of Medicine delves further into the link between prenatal SSRI exposure and adverse birth outcomes. Selective serotonin reuptake inhibitor drugs…
Today, I came across an article from the February, 2012 edition of The Australian and New Zealand Journal of Obstetrics and Gynecology published by F.J. Vajda and a team of researchers at University of Melbourne (Australia). In their piece, titled “The prescribing of antiepileptic drugs for pregnant Australian women.” Vajda et al. explore…
In the April, 2013 edition of JAMA, an article titled “Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism.” from a Danish team led by J. Christensen evaluated the risks of prenatal exposure to the antiepileptic Depacon. Because Abbott Laboratories, the manufacturer of this drug, failed time and…
Titled “Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register.”, an article by J. Morrow and a team from Belfast (UK) published in the February, 2006 edition of Journal of Neurology, Neurosurgery, and Psychiatry aimed to “assess the relative risk of major congenital malformation (MCM)…
In July, 2014, a team of Norwegian researchers led by K.O. Nakken published an article in Tidsskr Nor Laegeforen titled “Antiepileptic drugs and congenital malformations”, evaluating the consequences of prenatal exposure to epilepsy drugs containing sodium valproate, such as Depacon, Depakene, and Depakote (Abbott Laboratories, Inc.). To-date, dozens of…